Giovanni Peretto
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Genetic variants that impair cardiac function or predispose individuals to autoimmune diseases can influence both the risk and severity of inflammatory heart diseases, including lymphocytic myocarditis and cardiac sarcoidosis. We review recent clinical and experimental studies that describe the emerging interplay between genetic susceptibility and active myocardial inflammation. We summarize the current perspective on the mechanisms of inflammatory pathways and gene‐immune interactions, and explore the emerging therapeutic approaches aimed at targeting inflammation in genetic cardiomyopathies.
Year:
2026
BACKGROUND: Ventricular electrogram duration map (VEDUM) is a new approach for the identification of the arrhythmogenic substrate critical for ventricular tachycardia (VT), and it is based on the evaluation of the prolonged bipolar electrograms. Our aim is to evaluate the prognostic role of the VEDUM area in patients with VT and ischemic cardiomyopathy. METHODS: We enrolled all patients with ischemic cardiomyopathy who underwent VT ablation in 2 different centers. After isthmus transection for VT inducible, the procedure was aimed at noninducibility of any VT plus substrate modification. For each patient, we retrospectively analyzed the amount of the VEDUM area covered during catheter ablation. The primary outcome included any recurrence of sustained VT. RESULTS: Seventy-one patients (mean age: 69.9±8.9 years; males 93%) were enrolled. The mean size of the VEDUM area was 14.6±10.3 cm 2 , and it was visualized in a low voltage area in 65 (91.6%) patients. A deceleration zone and late potentials were recorded inside the VEDUM area in 71.8% and 73.2%, respectively. During a mean follow-up of 24.4±13.9 months, the primary outcome occurred in 18 (25.4%) cases; the arrhythmia free-survival was significantly lower in patients with ablation of at least 75% of the VEDUM area (VEDUM 75%: 89.5%; log-rank P value: 0.047). The ablation of at least 50% of the VEDUM area (hazard ratio, 0.374 [0.147–0.947]; P value, 0.038) and the VT inducibility (hazard ratio, 4.087 [1.341–12.450]; P value, 0.013) represented the only predictors of VT recurrence. CONCLUSIONS: VEDUM area ablation represented a new target for catheter ablation of VT in patients with ischemic cardiomyopathy.
Year:
2025
Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.
Year:
2025
Purpose: Myocarditis is frequently a sporadic disease, but may also occur in the context of genetic disorders which may increase susceptibility to cardiac inflammation. Cardiac involvement in Wolfram syndrome type 1 (WS1) has been scarcely characterized. To our knowledge, no cases of virus-negative myocarditis have been reported in the WS1 pediatric population. Methods: We report the description of a pediatric case of acute myocarditis in the context of WS1, followed by a literature review of cardiovascular involvement associated with wolframin variants, and discuss potential pathophysiological mechanisms and therapeutic options. Results: A young patient with WS1, treated with insulin and liraglutide, was admitted for acute chest pain. Cardiac magnetic resonance and endomyocardial biopsy were performed to confirm the clinical suspicion of myocarditis. While congenital heart diseases and arrhythmias have been described previously in patients with WS1, this is the first description of virus-negative myocarditis. Conclusions: Myocarditis may represent a possible manifestation of cardiovascular involvement in WS1. Cardiovascular screening may be considered in patients with WS1.
Year:
2024
Collaborators (31)
Arthur A M Wilde
University of Amsterdam
Nisha Gilotra
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Firat Duru
-
Kristina Haugaa
Professor
University of Oslo
A.s Amin
Cardiologist
Amsterdam University Medical Centers
Eric Smith
University of Michigan
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
J. Peter van Tintelen
Head Department; clinical geneticist
Universitair Medisch Centrum Utrecht
Matthew Taylor
Professor
University of Colorado Anschutz Medical Campus
Stefano Bianchi
Head of Unit
Fatebenefratelli Hospital
Lia Crotti
Director of the Cardiological Rehabilitation Unit, San Luca Hospital
IRCCS Istituto Auxologico Italiano
Victoria N. Parikh
Stanford University
Sing-Chien Yap
Researcher
Erasmus University Rotterdam
Michela Casella
Researcher
Università Politecnica delle Marche
Adam Helms
Assistant Professor
University of Michigan
Petros Syrris
University College London
James Ware
Professor
Imperial College London
Marco Merlo
University of Trieste
Marina Cerrone
Research Assistant Professor of Medicine
NYU School of Medicine
Gianfranco Sinagra
University of Trieste
Barbara Bauce
Associate Professor
University of Padova
Hugh Calkins
Johns Hopkins University School of Medicine
Cynthia James
Associate Professor
Johns Hopkins University
cristina basso
Professore Ordinario di Anatomia Patologica
University of Padova
Kalliopi Pilichou
Associate Professor
University of Padua
Ardan M. Saguner
-
Luisa Mestroni
Professor of Medicine
University of Colorado Anschutz Medical Campus
Juan Gimeno Blanes
Associate Professor
Universidad de Murcia
Marco Schiavone
Clinical Scientist
Centro Cardiologico Monzino
Perry Elliott
University College London
Leslie T Cooper
Professor
Mayo Clinic Florida
Make your next move.
Prepare your application
Review drafts before you send them.